Leukotriene E4
Based on 1 publication(s) in Google Scholar
Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.80%
- CAS No.: 75715-89-8
- 화학식: C23H37NO5S
- 분자량:439.61
-
보관:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
-
Help & FAQs
-
HY-113456
Leukotriene D4Bronchoconstrictor -
HY-113446
Leukotriene C4Endogenous Metabolite -
HY-125527
Resolvin D1Endogenous Inflammation Mediator -
HY-107609
BAY-u 9773Cysteinyl-Leukotriene Receptor Antagonist -
HY-117853
Atreleuton5-Lipoxygenase Inhibitor -
HY-17492
ZafirlukastLeukotriene Receptor Antagonist -
HY-13315A
MontelukastCysLT1 Antagonist -
HY-13315
Montelukast sodiumCysltr1 Antagonist -
HY-19989A
MK-571 sodiumABCC1/MRP4 Inhibitor -
HY-13315AR
Montelukast (Standard)CysLT1 Antagonist -
HY-15744
LY255283LTB4 Receptor Antagonist -
HY-105484
U-75302LTB4 inhibitor
Publications Citing Use of MedChemExpress (MCE) Leukotriene E4
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
제품 설명
IC50 & Target
|
Human Endogenous Metabolite |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
9.83 μM
Compound: Leukotrien E4
|
TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM) in membrane vesicles from Mrp2-expressing Sf9 cells
TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM) in membrane vesicles from Mrp2-expressing Sf9 cells
|
[PMID: 11306690] |
In Vitro
Leukotriene E4 induces only a very weak, non-sustained intracellular calcium mobilization response in LUVA human mast cells, with no detectable EC50[1].
Leukotriene E4 induces concentration-dependent intracellular calcium mobilization in HEK293T cells transfected with CYSLTR1, with an EC50 of 83.2 nM[1].
Leukotriene E4 (100 nM; 2-60 min) induces sustained phosphorylation of Erk in LAD2 human mast cells, and the activation signal remains detectable after 60 minutes[1].
Leukotriene E4 (100 nM; 2-60 min) induces transient phosphorylation of Erk in LUVA human mast cells, with no sustained activation observed within 60 minutes[1].
Leukotriene E4 (1-100 nM; 15 min) induces PTX-sensitive, MK571-resistant ERK phosphorylation in Chinese hamster ovary cells stably expressing human P2Y12 receptors, with activation initiating at 1 nM and reaching a plateau at 100 nM[2].
Leukotriene E4 (500 nM) induces calcium influx in LAD2 human mast cells, and this response is not inhibited by the P2Y12 antagonist 2-MesAMP (HY-125989)[2].
Leukotriene E4 (100 nM) induces the production of PGD2 in the human mast cell line LAD2, and the generation of this product is completely dependent on the P2Y12 receptor[2].
Leukotriene E4 (1 μM; 10 min) does not induce the expression of CD62P (an activation marker) in human blood platelets[2].
Leukotriene E4 (100 nM; 2-6 h) induces only extremely weak CCL4 mRNA and protein expression in LUVA human mast cells, with much lower potency relative to LTD4[1].
The induction of CCL4 mRNA expression in human mast cell line LAD2 by Leukotriene E4 (100 nM; 2 h) depends on the MEK/Erk pathway and intracellular/extracellular Ca2+, but is independent of Gi/o proteins or the PPAR-γ signaling pathway[1].
Leukotriene E4 (100 nM; 5 min-2 h) requires prolonged exposure (2 h) to induce full CCL4 mRNA expression in LAD2 human mast cells, whereas short-term exposure (5 min) only elicits weak activity[1].
Leukotriene E4 (100-500 nM; 6 h) induces high levels of MIP-1β production in LAD2 human mast cells, and this production process is mainly dependent on the P2Y12 receptor; the P2Y12 antagonist 2-MesAMP inhibits more than 50% of its production, while P2Y12 shRNA knockdown almost completely blocks this production process[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 75715-89-8
-
Appearance Liquid
-
분자량 439.61
-
화학식 C23H37NO5S
-
Color Colorless to light yellow
-
SMILES
CCCCC/C=C\C/C=C\C=C\C=C\[C@@H](SC[C@H](N)C(O)=O)[C@@H](O)CCCC(O)=O
-
Synonyms
LTE4
-
Structure Classification
-
Initial Source
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Solution, -20°C, 2 years
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Dec 18;16(1):11205. PMID: 41413034
순도&문서
-
Data Sheet (239 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Leukotriene E4 Related Classifications
HY-113465 Related Classifications
Powered by Bioz